Context: Polycystic ovary syndrome (PCOS) is associated with increased risk of endometrial cancer. This is usually explained by chronic anovulation and deficient progesterone activity. However, the role of progesterone receptors (PRs) in endometrial proliferation is unclear.
abnormalities have been attributed to chronic anovulation, a lack of progesterone, and, therefore, unopposed estrogen stimulation of the tissue (3) .
Progesterone protects the endometrium from estrogenstimulated proliferation via genomic pathways by the nuclear progesterone receptors (PRs) A and B (PRA and PRB) and via more rapid, nongenomic pathways such as progesterone receptor membrane component (PGRMC) 1 and PGRMC2 (4, 5) . The expression of both PRA and PRB in epithelial cells of the endometrium increases during the proliferative phase of the normal menstrual cycle and then gradually decreases during the secretory phase (4) . However, in stromal cells, the expression of PRA remains unchanged and PRB decreases during the secretory phase of the menstrual cycle (4). The 2 nuclear PRs seem to mediate different actions of progesterone in the uterus. From studies of receptor knockout mice, it is known that PRB promotes the hyperplasia of epithelial cells and PRA suppresses this effect (6) .
PGRMC1 and PGRMC2 are localized predominantly in the cytoplasm and are found in the stroma and luminal and glandular epithelium of the primate endometrium (7) . Expression of endometrial PGRMC1 and PGRMC2 was found to be differently regulated by estrogen and progesterone during the menstrual cycle (5) . Although PGRMC1 expression is greater during the proliferative phase and then gradually decreases during the secretory phase, the expression of PGRMC2 is greater in the secretory phase than in the proliferative phase (5) .
In women with PCOS, the endometrial expression of PRs, the distribution of PRs, and their functional role remain unclear. Data have suggested that the endometrium in PCOS women displays a reduced responsiveness to progesterone, which could explain the increased risk of hyperplasia and cancer (8) . In support, progesteroneregulated genes, including S100P, were found to be substantially lower in the endometrium of PCOS women despite treatment with clomiphene citrate or progesterone compared with controls (9) . Few studies have been reported on the expression of classic nuclear PRs in the endometrium of women with PCOS. In the study by Quezada et al. (10) , immunostaining of PRs in secretory endometrium was shown to be greater in PCOS women than in healthy controls. Furthermore, data are lacking regarding the expression of PGRMC1 and PGRMC2 receptors and their actions in the endometrium of women with PCOS.
A change in lifestyle is a first-line therapy for obese women with PCOS (11) . We have previously demonstrated that weight loss and exercise improves reproductive function (12, 13) , upregulates the endometrial gene and protein levels of molecules involved in insulin signaling (14) , and alters endometrial expression of estrogen and androgen receptors in women with PCOS (15) . The effect of lifestyle changes on the endometrial expression of PRs and proliferation is not known. The aim of the present study was to investigate genomic and nongenomic PRs in relation to proliferation, as determined by the proliferation marker Ki67, in the endometrium of women with PCOS.
Materials and Methods

Subjects
Women of reproductive age (18 to 40 years) fulfilling the 3 Rotterdam criteria for PCOS (i.e., oligo-or anovulation, hyperandrogenism, and polycystic ovaries) (16) and age-and body mass index (BMI)-matched controls were recruited from 2008 to 2012 at the Women's Health Research Unit at the Karolinska University Hospital (Stockholm, Sweden) (14, 15) . All the women were nonsmoking and were free of any hormonal treatment for $3 months before beginning the study. The exclusion criteria were pregnancy or lactation during the preceding 12 months, a current disease or endocrine disorder other than PCOS, eating disorders, and regular medication use, including insulin-sensitizing drugs.
Two groups were defined according to the presence of PCOS: women with PCOS and a BMI .27 kg/m 2 (OB-PCOS; n = 20) and healthy overweight or obese women with a BMI .27 kg/m 2 without PCOS (OB-C; n = 10). In the OB-PCOS group, all the women were initially anovulatory, presenting with either amenorrhea (no bleeding for the previous 3 months) or oligomenorrhea (5 to 9 periods during the previous year with intervals of .6 weeks). The women in the OB-C group had regular menstrual cycles.
Ethical approval
The local ethics committee approved the present study (approval no. 2008/865-32), and all participants provided written informed consent.
Intervention
The women in the OB-PCOS group, closely supervised by a dietician, underwent 3 months of an individually adapted lifestyle intervention program aimed at weight reduction (14, 15) . The participants were recommended a diet high in protein and low in carbohydrates [40% of energy (E%) carbohydrates, 30E% fat, and 30E% proteins] (11, 17) . A strict schedule of 3 main meals and 2 or 3 snacks daily was introduced. Food intake was self-reported and corrected, if needed.
All women in the OB-PCOS group received a membership to a local gym network. Furthermore, recommendations concerning the frequency, duration, and type of training exercise to increase physical activity were determined from each individual's condition, interest, and experience. An average physical activity included aerobic activity for 45 minutes 2 or 3 times per week, with participation recorded by the gym staff.
Experimental design
Before and after 3 months of the intervention, the women in the OB-PCOS group were examined on cycle days 6 to 8 and 21 to 23 of the menstrual cycle, which was determined by spontaneous menstruation or after induced bleeding (medroxyprogesterone acetate, 10 mg/d for 7 days). The women in the OB-C group were examined once, during a single menstrual cycle on cycle days 6 to 8 and 21 to 23. A fasting blood sample was collected at the same time from a peripheral vein and stored at 270°C for analysis of hormones and binding proteins. A gynecological examination, including transvaginal ultrasonography, was performed by the same investigator (A.L.H.) using Sonoline SL-250 equipment (Siemens Healthcare Diagnostics, Erlangen, Germany). After local anesthesia, biopsy specimens were collected using an endometrial suction curette (Pipet Curet; CooperSurgical, Trumbull, CT).
During the lifestyle intervention, the menstrual pattern of the women in the OB-PCOS group was recorded, and ovulation was confirmed by an elevated serum level of progesterone (.17 nmol/L) in the luteal phase of the menstrual cycle. The menstrual pattern was considered to be improved when a shift had occurred from amenorrhea to oligomenorrhea or regular menstruation or from oligomenorrhea to regular menstruation.
Specimens
The collected endometrial samples were divided into 2 pieces. One piece was preserved in RNAlater (Thermo Fisher Scientific Life Sciences, Waltham, MA) for further RNA isolation, and the second was fixed in 4% phosphate-buffered formaldehyde for 9 hours and then transferred to 70% ethanol for future embedding in paraffin.
Real-time polymerase chain reaction analysis
Real-time polymerase chain reaction (PCR) was performed in an iCycler iQ Real Time PCR System (Bio-Rad Laboratories, Inc., Hercules, CA). A reaction volume of 25 mL was used, containing complementary DNA corresponding to 50 ng RNA for PRAB, PGRMC1, PGRMC2, and S100P or 100 ng for PRB, 12.5 mL of iQ SYBR Green Supermix (Bio-Rad) and 0.3 mM of each oligonucleotide primer. The oligonucleotide primers for PRAB, PRB, PGRMC1, PGRMC2, S100P, and RPL13A (housekeeping gene) are presented in Supplemental Table 1 . All measurements were performed in duplicate. An RNA sample without reverse transcription was used as a negative control. The melting curve was used to control the purity of the PCR products (data not shown).
Immunohistochemistry
The protein expression of PRA, PRB, PGRMC1, PGRMC2, and Ki67 was evaluated. Immunostaining was performed on 5-mm-thick sections using a standard immunohistochemical technique (avidin-biotin-peroxidase), as previously described (18) . All the slides were blocked with normal horse serum diluted in phosphate-buffered saline. After blocking, the primary and secondary antibodies were applied. The primary and secondary antibodies and their dilutions and incubation times are listed in Supplemental Table 2 . Negative controls were obtained by replacing the primary antibody with the respective concentration of nonimmune immunoglobulin G from the same species.
Luminal epithelium, glandular epithelium, and stroma were evaluated separately. Depending on the protein localization, either image analysis or manual scoring was used. Nuclear immunostaining was evaluated by image analysis. For image analysis, a Leica microscope (Leica, Wetzlar, Germany) and Sony video camera (Sony, Park Ridge, NJ) connected to a computer with an image analysis system (Leica Imaging System Ltd., Cambridge, UK) were used. Cytosolic immunostaining was evaluated using the manual scoring, which was performed by 2 of us who were blinded to the group and order of sampling. For manual scoring, a 4-point grading scale was used: 2, negative; +, faint; ++, moderate; and +++, strong immunostaining.
Serum analyses
Serum concentrations of testosterone were analyzed using liquid chromatography/tandem mass spectrometry (LC-MS/MS) (19) . Free testosterone was calculated from the serum concentrations of total testosterone and sex hormone-binding globulin (SHBG), using a fixed albumin concentration of 40 g/L and successive computerized approximation involving a system of equation derived from the law of mass action (20) . Serum concentrations of luteinizing hormone (LH), folliclestimulating hormone (FSH), insulin, and SHBG were determined using chemiluminescent enzyme immunometric assays and estradiol using a sensitive radioimmunoassay, as previously described (13) . The detection limits and coefficients of variation within and between the assays were 0.1 nmol/L and 9.2% for testosterone, 0.7 U/L and 6% and 9% for LH, 0.1 U/L and 8% and 8% for FSH, 2.7 mIU/L and 3.0% and 4.0% for insulin, 0.2 nmol/L and 6.5% and 8.7% for SHBG, and 5 pmol/L and 3% and 6% for estradiol, respectively.
Statistical analysis
All values are expressed as mean 6 standard deviation or median and quartile range (25th to 75th percentile), depending on the distribution. Differences within groups were analyzed using the paired t test or Wilcoxon matched pairs test, depending on the distribution. Differences between .2 groups were evaluated using the Kruskal-Wallis test followed by Dunn's test, and differences between 2 groups were evaluated using the Mann-Whitney U test. Correlations between the variables were evaluated using Spearman's rank order correlation test. The significance level was set at P , 0.05.
Results
Before lifestyle intervention
Clinical characteristics on cycle days 6 to 8
Of the 20 obese women with PCOS, 18 completed the lifestyle intervention. The age and endocrinological parameters for the obese women with PCOS and their BMImatched controls are listed in Table 1 . As previously reported, the OB-PCOS group had significantly higher serum levels of total and free testosterone and lower levels of FSH and SHBG on cycle days 6 to 8 than the OB-C group (14, 15) . The endometrial thickness in the OB-PCOS women was not significantly different from that in the controls (Table 1) .
Gene and protein expression on cycle days 6 to 8
Messenger RNA (mRNA) expression of PRAB and PRAB/B (i.e., representing PRA) was lower and PRB expression was higher in the proliferative endometrium of OB-PCOS women compared with their BMI-matched controls (Table 1) . No statistically significant differences were found in either PGRMC1 mRNA or PGRMC2 mRNA levels between groups. Furthermore, we found no substantial differences in immunostaining between the groups for any of the proteins examined (data not shown), including the proliferative marker Ki67 (Table 1) .
After lifestyle intervention
Clinical characteristics
After the lifestyle intervention, body weight was significantly reduced in the OB-PCOS women (average of 5%), 6 OB-PCOS women had confirmed ovulation and luteal phase at cycle days 21 to 23, and 12 of the 18 OB-PCOS women were still anovulatory. As previously reported (14, 15) , OB-PCOS women with no luteal phase had higher serum levels of LH and FSH and lower levels of SHBG, estradiol, and progesterone on cycle days 21 to 23 compared with the OB-PCOS and OB-C groups with a confirmed luteal phase (Supplemental Table 3 ) (14, 15) . However, the serum levels of total testosterone were still higher in both subgroups of OB-PCOS women compared with the OB-C group (Supplemental Table 3 ) (14, 15). As expected, the serum progesterone levels were higher in the OB-PCOS women with a confirmed luteal phase than in the OB-PCOS women with no luteal phase (Supplemental Table 3 ) (14, 15) .
Gene expression on cycle days 6 to 8 and 21 to 23
No substantial changes were found in PR expression in the whole group of PCOS women on cycle days 6 to 8 after the lifestyle intervention (Supplemental Table 4 ). Moreover, mRNA expression of PRAB and PRAB/B in proliferative endometrium (cycle days 6 to 8) was still lower in the women with PCOS after the lifestyle intervention (P , 0.01 and P , 0.001, respectively). However, expression of PRB mRNA had changed and was no longer significantly different from that of the controls on cycle days 6 to 8. Figure 1 shows the gene expression of PRs on cycle days 6 to 8 and 21 to 23 in the endometrium of the OB-PCOS women with no luteal phase (n = 12), OB-PCOS women with a confirmed luteal phase (n = 6), and the control group. In the control group (OB-C), endometrial mRNA expression of PRAB, PRB, and PGRMC1 was lower on cycle days 21 to 23 compared with days 6 to 8 (Fig. 1) . In contrast, no substantial changes in these mRNA levels were evident between cycle days in the subgroups of OB-PCOS women without or with a confirmed luteal phase. The only exception was PGRMC2 mRNA expression, which was increased in the group of OB-PCOS women with a confirmed luteal phase and was higher than that in the OB-PCOS women with no luteal phase. However, PGRMC2 mRNA expression was not different from that seen in the controls (Fig. 1 ).
In the OB-PCOS group with no luteal phase, endometrial expression of PRAB, PRB, and PGRMC1 was higher and PRAB/B was lower on cycle days 21 to 23 compared with the controls (Fig. 1) . In the OB-PCOS group with a confirmed luteal phase, mRNA expression of PRAB and PRB was in between that of the other 2 groups and not significantly different from that in either the OB-PCOS women with no luteal phase or that in the controls (Fig. 1) . However, mRNA expression of PRAB/B Figure 1 . Relative mRNA expression of the nuclear receptors PRAB, PRB, PRAB/B ratio and the nongenomic receptors PGRMC1 and PGRMC2 after lifestyle intervention on cycle days 6 to 8 and 21 to 23 in the endometrium of obese women with PCOS and no luteal phase (OB-PCOS, no luteal phase, n = 12), obese women with PCOS and a confirmed luteal phase (OB-PCOS, confirmed luteal phase, n = 6), and age-and BMI-matched controls (OB-C, confirmed luteal phase, n = 10). Box and whisker plots represent the median and interquartile range (25th to 75th percentile). *P , 0.05, **P , 0.01, ***P , 0.001 indicating differences within groups; boxes with different letters indicate differences between groups (P , 0.05).
was still lower and PGRMC1 expression still higher than the expression in the controls (Fig. 1) .
Furthermore, the expression of S100P mRNA on cycle days 21 to 23 was lower in the group of OB-PCOS women with no luteal phase than that in the controls (median, 0.006; quartile range, 0.003 to 0.02; vs median, 0.9; quartile range, 0.03 to 4.0; P , 0.01). In contrast, the group of OB-PCOS women with a luteal phase exhibited expression of S100P mRNA that was not different from that of the controls (median, 0.01; quartile range, 0.04 to 0.7).
Protein expression on cycle days 21 to 23
Strong nuclear immunostaining of PRA, PRB, and Ki67 and moderate to strong cytosolic immunostaining of PGRMC1 and PGRMC2 was observed in all endometrial compartments (Fig. 2) . Because of a lack of tissue, 10 of 12 biopsy specimens in the group of OB-PCOS women with no luteal phase were used for protein expression analysis. In anovulatory OB-PCOS women, immunostaining of PRB, PGRMC1, and PGRMC2 in the stroma and of PGRMC1 in the luminal epithelium on cycle days 21 to 23 was significantly higher than in the controls (Figs. 2 and 3 ). In the OB-PCOS group with a confirmed luteal phase, only immunostaining of PRA was higher than that in the controls, for all 3 compartments (Fig. 3) .
In the control group, the proliferation marker Ki67 decreased in the epithelia but was increased in stroma in the secretory phase compared with the proliferative phase of the menstrual cycle (data not shown). In anovulatory OB-PCOS women, immunostaining of Ki67 on cycle days 21 to 23 was significantly greater in all endometrial compartments than in the BMI-matched controls (Figs. 2  and 3 ). Immunostaining of Ki67 in the OB-PCOS group with a confirmed luteal phase was not significantly different from that of any of the other groups (Fig. 3) .
Correlations on cycle days 21 to 23
In all subjects, on cycle days 21 to 23, the serum levels of progesterone correlated negatively with immunostaining of the proliferation marker Ki67 in the stroma, glandular epithelium, and luminal epithelium [ Fig. 4(A) ]. Moreover, in the same combined groups, Ki67 correlated positively with PRA and PRB in the stroma [ Fig. 4(B) ] and PGRMC1 (r = 0.40) and PGRMC2 (r = 0.54).
Discussion
To the best of our knowledge, the present study is the first to evaluate expression of endometrial PRs and proliferation, determined by the proliferation marker Ki67, in obese women with PCOS before and after a lifestyle intervention. Before the intervention, the PRAB mRNA level and PRAB/B ratio were lower and the PRB mRNA expression was higher in the proliferative endometrium of OB-PCOS women compared with their healthy BMI-matched controls. After the lifestyle intervention, PRB mRNA expression decreased and was not different from that of the controls on cycle days 6 to 8. In the subgroup of women with restored ovulation, only PRA immunostaining differed and was higher on cycle days 21 to 23, but the protein levels of PRB, PGRMC1, and PGRMC2 and the proliferative marker Ki67 were not different from those of the controls. OB-PCOS women who remained anovulatory had greater stromal immunostaining of PRB, PGRMC1, and PGRMC2 and the proliferation marker Ki67 compared with the BMI-matched controls.
The incidence of endometrial hyperplasia and cancer is increased in women with PCOS (21) and can be further aggravated by obesity (22) . Endometrial abnormalities in women with PCOS have mainly been attributed to chronic anovulation and a lack of antiproliferative action of progesterone (3) . During a normal menstrual cycle, progesterone initiates endometrial differentiation and prevents the endometrium from estrogen-driven Figure 2 . Representative images of PRA, PRB, PGRMC1, PGRMC2, and Ki67 immunoreactivity in the endometrium of OB-PCOS women with no luteal phase (OB-PCOS, no luteal phase, n = 10) and obese controls with a confirmed luteal phase (OB-C, confirmed luteal phase, n = 10) on cycle days 21 to 23.
proliferation (3) . Because progesterone action could be mediated via both nuclear and membrane-bound PRs, altered expression of these receptors might indicate impaired receptivity and contribute to the reduced fertility, endometrial hyperplasia, and cancer in obese women with PCOS. However, little is known about the Figure 3 . Immunohistochemistry scores of PRA, PRB, and Ki67, evaluated by image analyses, and PGRMC1 and PGRMC2, evaluated by manual scoring, in the endometrial stroma, glandular epithelium (GE), and luminal epithelium (LE) on cycle days 21 to 23 of obese PCOS women with no luteal phase (OB-PCOS, no luteal phase, n = 10), PCOS women with a confirmed luteal phase (OB-PCOS, confirmed luteal phase, n = 6), and obese controls with a confirmed luteal phase (OB-C, confirmed luteal phase, n = 10). Box and whisker plots represent the median and interquartile range (25th to 75th percentile). Different letters indicate differences between groups (P , 0.05).
coexpression of PRs and the proliferation marker Ki67 in the endometrium of these women.
In our study, the subgroup of OB-PCOS women who remained anovulatory after the lifestyle intervention exhibited increased mRNA expression of PRAB and PRB on cycle days 21 to 23 compared with the controls. Furthermore, the same group of OB-PCOS women had higher stromal immunostaining of PRB on the same cycle days compared with the controls. These findings might be explained by the absence of a regulatory effect of progesterone on nuclear PRs in anovulatory women. It is well documented that progesterone downregulates its own receptors in preparation for embryo implantation (3). Thus, a lack of progesterone might cause increased expression of PRs and endometrial dysfunction.
After the lifestyle intervention, ovulation was confirmed in one-third of the PCOS women. In contrast to the anovulatory women, the ovulatory subgroup displayed mRNA expression of PRAB and PRB that was not different from that of the controls. This finding is in agreement with a previous report in which PR mRNA expression in secretory endometrium of women with PCOS was not significantly different from that of the controls (10) . However, we found that the protein levels of PRA in the endometrium of OB-PCOS women with restored ovulation were significantly higher compared with the levels in the controls. The same finding of higher protein expression of PR in the mid-secretory endometrium has been reported previously for women with PCOS compared with controls (10) . Increased expression of PRs despite ovulation might indicate an impaired endometrial response to progesterone (9) . Although the possible mechanism of endometrial progesterone resistance remains to be clarified (23) , alterations in PR function and expression could lead to abnormal receptivity, poor reproductive function, and hyperplasia in the endometrium of women with PCOS.
To our knowledge, no information has been previously reported regarding membrane-bound PRs in the endometrium of PCOS women. We found that in the control group, PGRMC1 mRNA expression was significantly downregulated from cycle days 6 to 8 to cycle days 21 to 23. These results are in agreement with those from previous studies showing lower mRNA expression of PGRMC1 in the secretory phase compared with the proliferative phase of the menstrual cycle (5). Although both subgroups of OB-PCOS women exhibited higher gene expression of PGRMC1 in the endometrium on cycle days 21 to 23 compared with the controls, only the subgroup of anovulatory women with PCOS displayed protein levels of PGRMC1 and PGRMC2 significantly greater than those of the controls. Higher expression of endometrial PGRMC1 can be attributed to the lack of progesterone production in this group of women (5). However, the regulation and role of PGRMC1 and PGRMC2 in the endometrium of women with PCOS remain to be determined. Activation of progesterone signaling affects the gene expression pattern in the endometrium and its proliferative activity (9) . In our study, the anovulatory OB-PCOS women exhibited lower endometrial mRNA expression of the progesterone regulated gene S100P on cycle days 21 to 23. In contrast, in the subgroup of PCOS women with restored ovulation, the expression of S100P was not different from that of the controls. Moreover, expression of the proliferation marker Ki67 was higher in all endometrial compartments on cycle days 21 to 23 of the anovulatory PCOS women compared with that in the controls. In contrast, the subgroup of women with PCOS and restored ovulation had protein levels of Ki67 that were not different from those of the controls. The role of progesterone in regulating endometrial proliferation activity is well established (3). In our study, the progesterone levels correlated negatively with immunostaining of Ki67. Thus, it is likely that a progesterone-deficient milieu could explain the abnormal gene profile and greater proliferative activity in anovulatory obese PCOS women. Furthermore, a positive correlation between Ki67 and PRs in the stroma might suggest that higher expression of PRs in obese PCOS women is a compensatory response of the endometrium to increased proliferation activity.
Certain limitations of the present study must be recognized, such as the small number of subjects and the short intervention period. The strengths were the participation of a homogenous group of obese PCOS women fulfilling all 3 criteria of the Rotterdam consensus and age-and BMI-matched healthy controls. Furthermore, endometrial biopsy specimens were collected on standardized cycle days.
In conclusion, we have demonstrated that expression of PRAB mRNA and the PRAB/B ratio are lower in the proliferative endometrium of obese women with PCOS compared with expression in the controls. After a lifestyle intervention, PRAB mRNA expression was still low but expression of PRB mRNA had decreased and was not different from that of the controls in the proliferative endometrium. This change might indicate improved PR action and thereby endometrial function in women with PCOS after intervention. In contrast to the PCOS women who remained anovulatory, the group of women with PCOS and confirmed ovulation displayed protein expression of PRB, PGRMC1, and PGRMC2 and the proliferation marker Ki67 on cycle days 21 to 23 that was not different from that of the controls. Our findings might indicate that ovulation after lifestyle intervention alters, but does not fully restore, the expression of PRs in the endometrium of obese women with PCOS. We propose that impaired progesterone action in the endometrium can lead to proliferative abnormalities and an increased risk of cancer in women with PCOS.
